the biz of booze and buds

Houston-based cannabis company acquires favorite local brewery to launch full line of infused adult beverages

Two Houston companies have combined their businesses. Photo by Sergio Trevino

A Houston-based cannabis company has formalized its ongoing relationship with one of the city’s most popular breweries. Bayou City Hemp Company announced that it has purchased 8th Wonder Brewery, Distillery, and Cannabis.

The acquisition deepens a relationship that dates back to 2021, when 8th Wonder and Bayou City Hemp partnered to create Wonder Water, a non-alcoholic beverage available with either CBD or Delta-8 that became the top-selling to-go product at 8th Wonder.

Going forward, the combined company aims to capture a healthy share of the Texas market for adult beverages by offering a full lineup of beer, spirits, and cannabis-infused drinks.

“Our commitment to provide quality products and trusted brands to consumers is strengthened with 8th Wonder, who has been a Texas staple in craft beer and spirits for over a decade,” Bayou City CEO Benjamin Meggs said in a statement. “We look forward to growing market share and distribution to the entire portfolio of products through expanded resources and combined expertise. This is not merely an acquisition; it is a bold declaration of our intent to lead and innovate in the heart of Texas.”

The combined company aims to utilize 8th Wonder’s existing distribution channels to get its products on to as many store shelves as possible, including stores such as H-E-B, Walmart, Kroger, Total Wine, and Spec’s. A capital infusion from Bayou City Hemp will focus on marketing and promotion, helping the company to increase excitement for and awareness of the brand.

“Significant capital will be infused to build out the necessary infrastructure,” Meggs said in response to CultureMap’s request for comment about the combined company’s plans. “This infrastructure will enhance our operational capabilities positioning Bayou City to enter new emerging beverage categories such as Cannabis, NA Beer, and RTD Spirits [ready-to-drink] among others.”

While all those changes will mostly happen behind the scenes, customers will notice upgrades to the current 8th Wonder brewery, taproom, distillery, and beer garden to match the brand’s new look.

Founded in 2011, 8th Wonder Brewery evolved out of the Eatsie Boys food truck. Branded with a nostalgic affection for Houston, it developed a following for beers such as Dome Faux’m (cream ale), Rocket Fuel (Vietnamese coffee porter), and Haterade (gose). Over time, it expanded into spirits with a distillery and cannabis with a dispensary.

Bayou City Hemp Company opened in 2019. It produces edibles, vapes, additives, and seltzers that aim to meet the growing consumer demand for cannabis-based products.

Going forward, Meggs will remain in his role as CEO where he’ll be joined by Bayou City Hemp’s existing chief business officer, Jeromy Sherman, CFO Karen Trotter, chief revenue officer Joel Canada, and chief innovation officer Stephen Horton. 8th Wonder co-founder Ryan Soroka will serve as chief brand and marketing officer, while 8th Wonder co-founder and brewmaster Aaron Corsi will become COO.

“From day one at 8th Wonder, our goal was to build a hundred-year company,” Soroka added. “This transaction will provide the leadership and resources needed to achieve that dream. We look forward to a refreshed and revitalized 8th Wonder as we move forward with Bayou City Hemp into the exciting future of the beverage and cannabis industries.”

------

This article originally ran on CultureMap.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted